Compare stocks

Vita 34 AG, founded in 1997 and headquartered in Leipzig, Germany, specializes in the collection, processing, and long-term storage of stem cells from umbilical cord blood and tissue. The company offers cryopreservation services, enabling the storage of perinatal tissues for potential future medical therapies. Following its merger with PBKM, Vita 34 has expanded its focus to include investments in cell and gene therapies, as well as contract development and manufacturing organization (CDMO) services. Operating in approximately 50 countries, the company has stored around one million units of biological material. In 2023, Vita 34 reported revenues of €77.1 million, marking an 11.8% increase from the previous year.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.